BAX

N/A

Baxter International Inc.

Healthcare · Rank #499 · Analyzed Jul 13, 2026 (cached)

$19.89

Current Price

⚠️ Unverified — fails data-quality checks

This ticker did not clear our Definition of Done, so its valuation is shown for transparency but should not be trusted:

• Insufficient data to rate
• <2 valuation methods computed

$9.45

Intrinsic Value

-52.5%

Upside/Downside

0/10

Score

1/5

Quality

Analysis Summary

Valuation Consensus0/1 methods agree

Quality Score1/5.0

Framework RatingINSUFFICIENT DATA

Price vs Intrinsic ValueOvervalued by 52.5%

Fair Value Range

Low$9.45

Base (IV)$9.45

High$9.45

Entry Points

Conservative$6.62

Moderate$9.45

Aggressive$6.62

⚠️ Warnings

DCF discarded: negative profit margins
Insufficient data: fewer than 2 valuation methods

Quality & Moat Breakdown

Return on Equity-15.0% → 0/1.0

Debt LevelD/E 161 → 0/1.0

Revenue QualityGrowth 18.2%, margin Δ-16.9% +recovery → 1.0/1.0

Moat Strength1.0/5 → 0/1.0

Profit Margins-9.7% → 0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.